Wall Street brokerages expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share of ($1.15) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.23) and the highest estimate coming in at ($1.06). Atara Biotherapeutics posted earnings per share of ($0.63) in the same quarter last year, which suggests a negative year over year growth rate of 82.5%. The firm is scheduled to report its next quarterly earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($4.00) per share for the current year, with EPS estimates ranging from ($4.08) to ($3.91). For the next year, analysts expect that the business will report earnings of ($4.28) per share, with EPS estimates ranging from ($4.97) to ($3.59). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Atara Biotherapeutics.
ATRA has been the subject of a number of research reports. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub downgraded Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 3rd. Citigroup downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a report on Thursday. Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 6th. Finally, Canaccord Genuity restated a “positive” rating and issued a $70.00 price objective (up from $47.00) on shares of Atara Biotherapeutics in a report on Friday, January 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $30.60.
In related news, EVP Heather D. Turner sold 12,214 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $38.01, for a total value of $464,254.14. Following the completion of the sale, the executive vice president now directly owns 77,112 shares in the company, valued at $2,931,027.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Isaac E. Ciechanover sold 48,500 shares of the stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $34.58, for a total value of $1,677,130.00. Following the sale, the chief executive officer now owns 348,978 shares of the company’s stock, valued at $12,067,659.24. The disclosure for this sale can be found here. Insiders sold 290,914 shares of company stock valued at $7,969,587 over the last 90 days. 16.20% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC acquired a new stake in Atara Biotherapeutics during the 4th quarter worth about $217,000. Nexthera Capital LP acquired a new stake in Atara Biotherapeutics during the 4th quarter worth about $5,188,000. Raymond James & Associates grew its holdings in Atara Biotherapeutics by 7.3% during the 4th quarter. Raymond James & Associates now owns 25,325 shares of the biotechnology company’s stock worth $458,000 after acquiring an additional 1,719 shares during the period. Bridger Management LLC grew its holdings in Atara Biotherapeutics by 57.3% during the 4th quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company’s stock worth $47,035,000 after acquiring an additional 946,086 shares during the period. Finally, California State Teachers Retirement System grew its holdings in Atara Biotherapeutics by 4.6% during the 4th quarter. California State Teachers Retirement System now owns 42,159 shares of the biotechnology company’s stock worth $763,000 after acquiring an additional 1,836 shares during the period. Hedge funds and other institutional investors own 74.29% of the company’s stock.
Shares of Atara Biotherapeutics (ATRA) traded down $1.65 during midday trading on Wednesday, reaching $45.40. The company’s stock had a trading volume of 810,300 shares, compared to its average volume of 1,258,830. The firm has a market capitalization of $1,706.85, a P/E ratio of -13.08 and a beta of 2.71. Atara Biotherapeutics has a 1 year low of $11.80 and a 1 year high of $49.90.
ILLEGAL ACTIVITY NOTICE: “Atara Biotherapeutics Inc (ATRA) Expected to Post Earnings of -$1.15 Per Share” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/19/atara-biotherapeutics-inc-atra-expected-to-post-earnings-of-1-15-per-share.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.